News
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Tharimmune, Inc. strengthens operational leadership, secures $5.47 million in financing, advances TH104 for national security against Fentanyl, and pioneers oral antibody medication TH023 for inflammation. Company highlights advancements in corporate governance -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
Tharimmune, Inc. announces key leadership appointments and progress on pipeline development, including lead candidate TH104 for opioid antagonist delivery in high-risk scenarios -
-
